{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:53:31Z","timestamp":1792612411251,"version":"4.5.0"},"reference-count":43,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.5582\/bst.2024.01369","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T22:11:13Z","timestamp":1739052673000},"page":"116-124","source":"Crossref","is-referenced-by-count":9,"title":["Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease"],"prefix":"10.5582","volume":"19","author":[{"given":"Chien-Tai","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan."},{"name":"Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan."},{"name":"Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen\u2010Chih","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan."},{"name":"Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan."},{"name":"Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Ph.D in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson&apos;s disease. Lancet Neurol. 2021; 20:385-397.","DOI":"10.1016\/S1474-4422(21)00030-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Le W, Dong J, Li S, Korczyn AD. Can Biomarkers Help the Early Diagnosis of Parkinson&apos;s Disease? Neurosci Bull. 2017; 33:535-542.","DOI":"10.1007\/s12264-017-0174-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. T T\u00f6nges L, Buhmann C, Klebe S, Klucken J, Kwon EH, M\u00fcller T, Pedrosa DJ, Schr\u00f6ter N, Riederer P, Lingor P. Blood-based biomarker in Parkinson&apos;s disease: potential for future applications in clinical research and practice. J Neural Transm (Vienna). 2022; 129:1201-1217.","DOI":"10.1007\/s00702-022-02498-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Morris HR. Blood based biomarkers for movement disorders. Acta Neurol Scand. 2022; 146:353-361.","DOI":"10.1111\/ane.13700"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cova I, Priori A. Diagnostic biomarkers for Parkinson&apos;s disease at a glance: where are we? J Neural Transm (Vienna). 2018; 125:1417-1432.","DOI":"10.1007\/s00702-018-1910-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson&apos;s disease: Advances and strategies. Parkinsonism Relat Disord. 2016; 22 Suppl 1:S106-110.","DOI":"10.1016\/j.parkreldis.2015.09.048"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wang C, Liu H. Factors influencing degradation kinetics of mRNAs and half-lives of microRNAs, circRNAs, lncRNAs in blood <i>in vitro<\/i> using quantitative PCR. Sci Rep. 2022; 12:7259.","DOI":"10.1038\/s41598-022-11339-w"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin Appl. 2008; 2:1386-1402.","DOI":"10.1002\/prca.200780174"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24:971-983.","DOI":"10.1038\/nbt1235"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer&apos;s disease: challenging but feasible. Biomark Med. 2010; 4:65-79.","DOI":"10.2217\/bmm.09.84"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Howell JC, Parker MW, Watts KD, Kollhoff A, Tsvetkova DZ, Hu WT. Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience. Front Aging Neurosci. 2016; 8:296.","DOI":"10.3389\/fnagi.2016.00296"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tsvetkova DZ, Bergquist SH, Parker MW, Jarrett TL, Howell JC, Watts KD, Kollhoff A, Roberts DL, Hu WT. Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort. Front Aging Neurosci. 2017; 9:22.","DOI":"10.3389\/fnagi.2017.00022"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chan L, Chung CC, Hsieh YC, Wu RM, Hong CT. Plasma extracellular vesicle tau, \u03b2-amyloid, and \u03b1-synuclein and the progression of Parkinson&apos;s disease: a follow-up study. Ther Adv Neurol Disord. 2023; 16:17562864221150329.","DOI":"10.1177\/17562864221150329"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chung CC, Chan L, Chen JH, Bamodu OA, Chiu HW, Hong CT. Plasma extracellular vesicles tau and \u03b2-amyloid as biomarkers of cognitive dysfunction of Parkinson&apos;s disease. FASEB J. 2021; 35:e21895.","DOI":"10.1096\/fj.202100787R"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Y\u00e1\u00f1ez-M\u00f3 M, Siljander PR, Andreu Z. <i>et al<\/i>. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4:27066.","DOI":"10.3402\/jev.v4.27066"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015; 9:358-367.","DOI":"10.1002\/prca.201400114"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. J Jin Y, Chen K, Wang Z. <i>et al<\/i>. DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer. 2016; 16:753.","DOI":"10.1186\/s12885-016-2783-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014; 19:1568-1575.","DOI":"10.3390\/molecules19021568"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Haqqani AS, Delaney CE, Tremblay TL, Sodja C, Sandhu JK, Stanimirovic DB. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS. 2013; 10:4.","DOI":"10.1186\/2045-8118-10-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Noguchi-Shinohara M, Ono K. The Mechanisms of the Roles of \u03b1-Synuclein, Amyloid-\u03b2, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics. Int J Mol Sci. 2023; 24:10215.","DOI":"10.3390\/ijms241210215"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sengupta U, Kayed R. Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022; 214:102270.","DOI":"10.1016\/j.pneurobio.2022.102270"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, Lees AJ, Revesz T. The Significance of \u03b1-Synuclein, Amyloid-\u03b2 and Tau Pathologies in Parkinson&apos;s Disease Progression and Related Dementia. Neurodegenerative Diseases 13, 154-156 (2013).","DOI":"10.1159\/000354670"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson&apos;s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023; 14:176.","DOI":"10.1038\/s41419-023-05672-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson&apos;s disease-related pathology. Cell Tissue Res. 2004; 318:121-134.","DOI":"10.1007\/s00441-004-0956-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pan L, Meng L, He M, Zhang Z. Tau in the pathophysiology of Parkinson&apos;s disease. J Mol Neurosci. 2021; 71:2179-2191.","DOI":"10.1007\/s12031-020-01776-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lim EW, Aarsland D, Ffytche D, Taddei RN, van Wamelen DJ, Wan YM, Tan EK, Ray Chaudhuri K; Kings Parcog group MDS Nonmotor study group. Amyloid-\u03b2 and Parkinson&apos;s disease. J Neurol. 2019; 266:2605-2619.","DOI":"10.1007\/s00415-018-9100-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hepp DH, Vergoossen DL, Huisman E, Lemstra AW; Netherlands Brain Bank; Berendse HW, Rozemuller AJ, Foncke EM, van de Berg WD. Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with lewy bodies. J Neuropathol Exp Neurol. 2016; 75:936-945.","DOI":"10.1093\/jnen\/nlw070"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. CSF and blood biomarkers for Parkinson&apos;s disease. Lancet Neurol. 2019; 18:573-586.","DOI":"10.1016\/S1474-4422(19)30024-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Xylaki M, Chopra A, Weber S, Bartl M, Outeiro TF, Mollenhauer B. Extracellular vesicles for the diagnosis of Parkinson&apos;s disease: Systematic review and meta-analysis. Mov Disord. 2023; 38:1585-1597.","DOI":"10.1002\/mds.29497"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Marsden CD. Parkinson&apos;s disease. J Neurol Neurosurg Psychiatry. 1994; 57:672-681.","DOI":"10.1136\/jnnp.57.6.672"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson&apos;s disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord. 2011; 26:416-423.","DOI":"10.1002\/mds.23468"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Honson NS, Kuret J. Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J Alzheimers Dis. 2008; 14:417-422.","DOI":"10.3233\/JAD-2008-14409"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Roy RG, Mandal PK, Maroon JC. Oxidative stress occurs prior to amyloid A\u03b2 plaque formation and tau phosphorylation in Alzheimer&apos;s disease: Role of glutathione and metal ions. ACS Chem Neurosci. 2023; 14:2944-2954.","DOI":"10.1021\/acschemneuro.3c00486"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Coughlin DG, Irwin DJ. Fluid and biopsy based biomarkers in Parkinson&apos;s disease. Neurotherapeutics. 2023; 20:932-954.","DOI":"10.1007\/s13311-023-01379-z"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Shi M, Zhang J. CSF \u03b1-synuclein, tau, and amyloid \u03b2 in Parkinson&apos;s disease. Lancet Neurol. 2011; 10:681; author&apos;s reply 681-3.","DOI":"10.1016\/S1474-4422(11)70161-2"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology. 2019; 93:e1104-e1111.","DOI":"10.1212\/WNL.0000000000008088"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson&apos;s disease. Parkinsonism Relat Disord. 2014; 20 Suppl 1:S99-103.","DOI":"10.1016\/S1353-8020(13)70025-7"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Joo J, Jeong J, Park HJ. Blood Biomarkers in Patients with Parkinson&apos;s Disease: A Review in Context of Anesthetic Care. Diagnostics (Basel). 2023; 13:693.","DOI":"10.3390\/diagnostics13040693"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Lin CH, Liu HC, Yang SY, Yang KC, Wu CC, Chiu MJ. Plasma pS129-\u03b1-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson&apos;s Disease. J Clin Med. 2019; 8:1601.","DOI":"10.3390\/jcm8101601"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, Mann DM, Allsop D. A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson&apos;s disease. Sci Rep. 2013; 3:2540.","DOI":"10.1038\/srep02540"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Niu M, Li Y, Li G, Zhou L, Luo N, Yao M, Kang W, Liu J. A longitudinal study on \u03b1-synuclein in plasma neuronal exosomes as a biomarker for Parkinson&apos;s disease development and progression. Eur J Neurol. 2020 ;27:967-974.","DOI":"10.1111\/ene.14208"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Zhao ZH, Chen ZT, Zhou RL, Zhang X, Ye QY, Wang YZ. Increased DJ-1 and \u03b1-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson&apos;s Disease. Front Aging Neurosci. 2019; 10:438","DOI":"10.3389\/fnagi.2018.00438"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Attems J, Jellinger K. Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res. 2013; 10:569-577.","DOI":"10.2174\/15672050113109990002"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/1\/19_2024.01369\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T04:17:51Z","timestamp":1741407471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/1\/19_2024.01369\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2024.01369","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"2024.01369"}}